Rigel’s Q3 2026: VEPPANU Takes the Spotlight as RIGL Bets on a Growth Runway

Ticker: RIGL. In Rigel Pharmaceuticals’ third quarter 2026 results, the headline figures include EPS context to come, while the company lays out a multi-pronged growth plan centered on VEPPANU (vepdegestrant) and the R289 program. The press release highlights a total revenue print of $80.9 million, with net income of $13.2 million, and a split of net product sales versus collaboration revenue that tells you where the business is headed next.

What Rigel reported

For the quarter ended September 30, 2026, Rigel posted $80.9 million in total revenues and net income of $13.2 million. Net product sales amounted to $72.3 million, while contract revenues from collaborations were $8.6 million, underscoring a tilt toward product-driven cash flow as the company scales its commercial capability.

On the product side, VEPPANU became commercially available in mid-August and generated $6.6 million in initial net product sales for the quarter. In the six weeks since launch, Rigel shipped VEPPANU to more than 100 patients and clinics, with early signs of refill activity that suggest patient and prescriber interest. The company notes that this is the first meaningful commercial inflection for a portfolio that includes TAVALISSE, REZLIDHIA, GAVRETO, and VEPPANU.

The press release also highlights ongoing development: the Phase 1b study of R289, Rigel’s dual IRAK1/4 inhibitor, in patients with lower-risk myelodysplastic syndromes (MDS) remains ongoing, with plans to select the recommended Phase 2 dose by the end of 2026. In addition, an oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in lower-risk MDS.

Outlook and the economics of execution

Rigel reaffirmed its 2026 revenue forecast of roughly $290 to $295 million in total revenues. Within that, net product sales are expected to be $255 to $260 million (excluding VEPPANU), with contract revenues from collaborations of about $35 million. The guidance signal is clear: VEPPANU’s ramp will be a meaningful driver of the top line, while the core product sales backbone (TAVALISSE, REZLIDHIA, GAVRETO) remains a steady contributor to cash flow.

The company did not publish EPS or an explicit EPS consensus in the release, leaving per-share results to the next quarterly update. In the meantime, the revenue mix shift toward VEPPANU and the potential uplift from R289’s Phase 1b data will be the focal point for investors and analysts, particularly as ASH data arrives in December.

What it means for Rigel’s strategy and the field

The VEPPANU launch represents a notable inflection in Rigel’s commercial trajectory. A drug generally started only a few months ago now sits at the center of the company’s forecast for 2026 and beyond, with early uptake bridging the gap between development-stage hopes and revenue certainty. The EPS pathway remains contingent on the extent to which VEPPANU can sustain above-physician adoption and refills, while the R289 program could unlock additional upside if the Phase 1b data point toward a compelling Phase 2 dose and a favorable safety profile.

From a sector lens, Rigel’s dual-pronged approach—commercializing a newer asset while continuing late-stage exploration for a disease-modifying signal—offers a blueprint for other mid-stage biotechs navigating the transition from pipeline to profitability. If VEPPANU’s early performance translates into durable demand, peers with complementary hematologic or oncology franchises may recalibrate expectations around launch timing, payer dynamics, and the sequencing of clinical milestones.

Risks and catalysts to watch

The most immediate risk is whether VEPPANU’s early traction can be sustained as it scales beyond initial six-week data. Manufacturing capacity, payer uptake, and competitive dynamics in the beta-aligned hematology space will influence whether the revenue forecast can be realized without upward revision. The R289 program remains a wildcard: the ability to complete a dose selection by year-end 2026 would strengthen the narrative, but failure to hit that milestone or adverse safety signals could temper enthusiasm.

Investors will want to see quarterly progress on EPS and margin leverage as the mix shifts toward product sales. The EPS consensus will matter less for this quarter than the trajectory of top-line growth and the sustainability of VEPPANU’s early momentum. The ASH data drop in December is a high-visibility catalyst that could recalibrate expectations for 2027 and beyond.

Bottom line

Rigel’s Q3 2026 results present a narrative of early commercial validation for VEPPANU and a pipeline plan that hinges on R289. The company appears to be aligning its revenue mix with a longer-term growth story, anchored by a mid- to late-2020s revenue forecast and a strategic emphasis on selection of a Phase 2 dose for R289. For sector peers, the takeaway is clear: successful launches with meaningful early traction can reshape forecasts even before substantial post-launch data accumulate, and the interplay between product sales and collaboration revenue will continue to drive the narrative for biopharma cash flow in the near term.

Next catalysts include the December ASH updates on R289 and Rigel’s forthcoming quarterly results, where investors will finally get more clarity on EPS and EPS consensus alignment with the company’s updated revenue trajectory.